Literature DB >> 26089036

Factors influencing inclusion in digestive cancer clinical trials: A population-based study.

Mathilde Frérot1, Valérie Jooste1, Christine Binquet2, Isabelle Fournel2, Laurent Bedenne3, Anne-Marie Bouvier4.   

Abstract

BACKGROUND: Inclusion in a randomized therapeutic trial represents an optimal therapeutic strategy. AIMS: To determine the influence of demographic characteristics and deprivation on the enrolment of patients in digestive cancer clinical trials.
METHODS: Between 2004 and 2010, 4632 patients were recorded by the Burgundy Digestive Cancer Registry. According to a balancing score, the 136 patients included in a clinical trial were matched with 272 patients who met the eligibility criteria for trials. Deprivation was measured by the ecological European deprivation index. A conditional multivariate logistic regression was performed.
RESULTS: Patients aged over 75 years were significantly less likely to be included in clinical trials than younger patients (odds ratio 0.33; [0.13-0.87]). Patients treated in private institutions were also less likely to be enrolled than those treated in public institutions (odds ratio 0.04; [0.01-0.16]; p<0.001). A relationship between type of institution and the European deprivation index was observed (p=0.017). Deprived patients were less likely to be included in clinical trials when they were managed in private institutions (odds ratio 0.706; [0.524-0.952]; p=0.022). The European deprivation index had no impact when patients were managed in other institutions.
CONCLUSION: The relationship between type of institution and deprivation underlines the necessity for improving patients' chance of being recruited in digestive cancer clinical trials.
Copyright © 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clinical trial; Digestive cancers; Registries; Socio-economic factors

Mesh:

Year:  2015        PMID: 26089036     DOI: 10.1016/j.dld.2015.05.017

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  5 in total

1.  Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective.

Authors:  P-F Zhang; F Wen; J Zhou; J-X Huang; K-X Zhou; Q-J Wu; X-Y Wang; M-X Zhang; W-T Liao; Q Li
Journal:  Clin Transl Oncol       Date:  2019-05-06       Impact factor: 3.405

2.  Health Literacy and Clinical Trial Participation in French Cancer Patients: A National Survey.

Authors:  Youssoufa M Ousseine; Anne-Déborah Bouhnik; Julien Mancini
Journal:  Curr Oncol       Date:  2022-04-28       Impact factor: 3.109

3.  Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries.

Authors:  Alix Augustin; Steven Le Gouill; Rémy Gressin; Aurélie Bertaut; Alain Monnereau; Anne-Sophie Woronoff; Brigitte Trétarre; Patricia Delafosse; Xavier Troussard; Anne Moreau; Olivier Hermine; Marc Maynadié
Journal:  J Cancer Res Clin Oncol       Date:  2017-10-11       Impact factor: 4.553

4.  Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.

Authors:  T Aparicio; O Bouché; J Taieb; E Maillard; S Kirscher; P-L Etienne; R Faroux; F Khemissa Akouz; F El Hajbi; C Locher; Y Rinaldi; T Lecomte; S Lavau-Denes; M Baconnier; A Oden-Gangloff; D Genet; E Paillaud; F Retornaz; E François; L Bedenne
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

5.  A nomogram for predicting cancer-specific survival in different age groups for operable gastric cancer: a population-based study.

Authors:  Shuai Guo; Mu-Yan Shang; Zhe Dong; Jun Zhang; Yue Wang; Zhi-Chao Zheng; Yan Zhao
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.